Background: Patients with oesophago-gastric (OG) cancer may be at risk of malnutrition, troublesome gastrointestinal symptoms (GI) and reduced dietary intake in view of the tumour location and multimodality curative treatment approach. Longitudinal research is lacking. The present study aimed to assess (i) nutritional status and how it evolved over the first year; (ii) the association between nutritional status scores and GI symptom scores; and (iii) the nutrient and food group intake pattern. Methods: This was a prospective, observational study of patients with an OG lesion planned for radical treatment, with assessment at diagnosis, 3 months and 12 months after the start of treatment. Nutritional assessment was performed using the Patient-Generated Subjective Global Assessment, GI symptoms measured using the modified Gastrointestinal Symptom Rating Scale and dietary intake assessed using a semi-quantitative food frequency approach. Results: Eighty patients (61 males, 19 females; aged 46-89 years) were recruited. At baseline, 3 (n = 68) and 12 months (n = 57), 61%, 62% and 60%, respectively, were moderately/severely malnourished. Higher symptom burden was associated with poorer nutritional status at baseline (r = 0.55, P < 0.001), 3 months (r = 0.51, P < 0.001) and 12 months (r = 0.42, P = 0.001). At each respective time point, 37%, 38% and 42% were meeting their estimated average requirement for energy. No change in mean (SD) intake of energy, fibre, nutrient and food groups was observed over time. Conclusions: Patients with OG cancer have progressive weight loss, with malnutrition present over the majority of the 12-month study period. Optimising nutritional status and symptom management throughout the treatment pathway should be a clinical priority.
Introduction
Disease-related malnutrition occurs frequently in patients with cancer, with a high incidence in patients with oesophago-gastric (OG) cancer, ranging from 37% to 63% (1) (2) (3) . The prevalence is dependent on tumour type and location, disease staging, treatment received and type of nutritional assessment method used (4, 5) . Most prevalence data are cross-sectional, and do not account for variations in nutritional status and malnutrition at different stages of treatment. The consequences of malnutrition in cancer are well recognised and include important adverse effects on clinical outcome; for example, an increased risk of morbidity, decreased response and tolerance to treatment, decreased performance status and lower quality of life (6) (7) (8) (9) (10) . It is likely that malnutrition and nutritional deterioration in OG cancer are the result of a dual mechanism, whereby negative local and systemic effects of the disease are compounded by acute and chronic nutrition impact symptoms produced by treatments. Such treatment involves a combination of chemotherapeutic, radiotherapeutic and surgical regimens. A high burden of gastrointestinal (GI) symptoms is observed, although their co-occurrence and potential causal connection with malnutrition remain unclear (11) (12) (13) . Likewise, an inadequate oral intake may contribute to malnutrition in OG cancer, although few studies have assessed dietary intake and those that do are very heterogeneous, using different dietary assessment methods and presenting conflicting results (14) (15) (16) . Therefore, the contribution of inadequate oral intake to malnutrition in patients with OG cancer is uncertain.
To date, the nutritional status, GI symptom burden or dietary intake of OG cancer patients has not been systematically measured longitudinally. The present study aimed to (i) assess nutritional status and the prevalence of malnutrition at diagnosis and in the early (3 months) and later stages (12 months) of treatment; (ii) determine the association between GI symptom scores and nutritional status and malnutrition; and (iii) assess nutrient and food group intake and its association with nutritional status and malnutrition.
Materials and methods
Subjects and study design A prospective, longitudinal cohort study of patients with a new oesophageal, gastro-oesophageal or gastric cancer (or premalignant disease of these locations) was conducted at a tertiary cancer centre in the UK: The Royal Marsden NHS Foundation Trust. Eligibility criteria were: cancer/premalignant disease confirmed by histopathology; planned to undergo radical treatment. Exclusion criteria were: age <18 years; receiving private health care; previous OG cancer; oncological treatment started >1 week before consent; and unable to provide informed consent.
Each patient with a new OG cancer diagnosis was discussed at a weekly OG specialist multidisciplinary team meeting at the tertiary cancer centre. Here, a treatment plan was established for each individual, and the study's registered dietitian screened patients to identify those fulfilling the study's inclusion criteria. Given the vulnerability of the patient group, the study dietitian liaised with other members of the multidisciplinary team to determine the most appropriate time for her to approach eligible patients. This was often at one of their routine outpatient appointments with their oncologist or surgeon.
Patients provided their informed consent before study enrolment, with recruitment from 18 November 2011 to 17 May 2013. The study visits were at diagnosis (before starting treatment) and at 3 and 12 months after the treatment start date. Measurements of nutritional status, GI symptoms and dietary intake were taken by the same study dietitian at each time point.
The study was reviewed and approved by the institutional clinical research and local ethics committees. The procedures followed were in accordance with the Helsinki Declaration of 1975 as revised in 1983.
Nutritional status
Weights and heights were measured by the study dietitian using the Marsden M-120 Column Scales and the Marsden HM-200 Telescopic Height Measure (Marsden Weighing Machine Group Limited, Rotherham, UK). The equipment was serviced and calibrated every 6 months by the manufacturer of the equipment. When measuring weight, the scales were positioned on a level surface, and the patient removed their shoes and wore light day clothing (items in pockets and jewellery were removed). The presence of ascites and/or oedema was noted and, where present, an estimated weight was recorded.
Nutritional assessment was undertaken using the PatientGenerated Subjective Global Assessment (PG-SGA) (17) . This is the only validated and specific tool for a thorough nutritional assessment in oncology and has been accepted as the standard for nutrition assessment in oncology.
The PG-SGA has two sections: a patient-completed component and a clinician component. The former has four parts (weight loss, nutrition impact symptoms, nutritional intake and functional capacity). The later also has four parts, which produces scores for diagnosis, age and metabolic stress, as well as a subjective physical examination assessing fat, muscle stores and fluid status. Finally, a global assessment of nutritional status is produced.
The PG-SGA produces both subjective global ratings and a PG-SGA total score. The subjective global rating categories are consistent with the three categories from the SGA tool: PG-SGA-A (well-nourished), PG-SGA-B (moderately/suspected malnourished) and PG-SGA-C (severely malnourished). PG-SGA total scores range from 0 to 49, with triage recommendations as follows: score 0-1 (no intervention required); score 2-3 (patient and family education with pharmacological intervention and/ or laboratory values); score 4-8 (requires intervention by dietitian in conjunction with nurse or physician); and score ≥9 (critical need for improved symptom management and/or nutrient intervention options).
For ethical reasons, standard clinical practice was followed regarding dietary intervention in study patients. Accordingly, members of the multidisciplinary team were able to refer patients to a separate clinical dietitian based upon their own clinical opinion. The study dietitian would also refer patients to the clinical dietitian in those with a PG-SGA total score of ≥4.
Gastrointestinal symptoms
Presence and severity of GI symptoms were measured using a modified version of the original 15-symptom Gastrointestinal Symptom Rating Scale (GSRS) (18) . The purpose of modification was to increase the time over which the tool captures symptoms and to make it more disease-specific by adding relevant symptoms (dysphagia to fluids and/or solids, odynophagia to fluids and/or solids, early satiety, regurgitation of fluids and/or solids, faecal incontinence) and by removing symptoms considered irrelevant (hunger pains and sucking sensation in epigastrium). The modified tool measured 22 GI symptoms over the previous 4 weeks using a four-point Likert scale (0 = absent symptom; 1 = mild symptom occurring occasionally but not impacting much; 2 = moderate symptom occurring often and impacting quite a bit; and 3 = severe symptom occurring often and impacting a great deal). Individual scores were recorded for each GI symptom, and the sum of all 22 GI symptom scores was used to produce a GSRS total score (potential minimum score of 0 and maximum of 66).
Dietary intake
The dietary assessment tool was the European Prospective Investigation into Cancer Food Frequency Questionnaire (FFQ) (Norfolk version). This is a semi-quantitative FFQ validated for assessing habitual dietary intake for the previous 12 months in the European Prospective Investigation into cancer population (19) (20) (21) (22) . This FFQ contains a list of 130 foods items and a multiple response grid. Food lists and portion sizes are representative of an adult population in the UK following a traditional diet. Patients were requested to complete the FFQ based upon intake over the previous 1 month (rather than over the previous 12 months) to ensure alignment with the study design.
Data entry and analysis of the FFQs were undertaken using FETA software (23) to produce nutrient and food group intake data. Data on intake of vitamin and micronutrient supplements, oral nutritional supplements and enteral nutrition were collected but could not be computed using the FETA software. The data presented are for oral intake from food exclusively.
Statistical analysis
Because this was an observational study, with no group comparisons and no reporting of effect size, it was not necessary to power the study. A maximum recruitment period of 18 months was possible. No missing data were replaced. Statistical analyses were conducted using the SPSS, version 22.0 (IBM Corp., Armonk, NY, USA). Paired continuous data were compared using paired t-tests. P < 0.05 (two-sided) was considered statistically significant. The Kolmogorov-Smirnov test was used to examine the distribution of GSRS total scores and PG-SGA total scores, both of which were non-normally distributed. Median and range were used to summarise the data, and the data were compared between different time points using nonparametric tests (Wilcoxon test). All other data were normally distributed.
The change in patient PG-SGA category between baseline and 3 months and between baseline and 12 months was assessed using cross-tabulation.
The association between GI symptoms and nutritional status was measured in three ways. The association between overall GI symptoms (GSRS total scores) and nutritional status (PG-SGA total scores) was analysed using Spearman's rank correlation. Data were visualised using scatter plots, and Dancey and Reidy's categorisations aided the determination of the strength of the correlation using correlation coefficients (r) (24) . The nutritional status (PG-SGA total scores) of patients with (mild/moderate/severe) and without (absence) each of the GI symptoms was compared using a chi-squared test. Finally, cross-tabulation was performed to compare those with the presence (i.e. mild, moderate or severe) and the absence of each GI symptom measured with respect to malnutrition category (PG-SGA A and PG-SGA B + C).
Descriptive analysis was undertaken to report the FFQ data using the mean (SD) intake of energy, macronutrients, micronutrients and fibre and 14 food groups. For those with three FFQs, repeated measures analysis of variance compared the intakes at the three time points and, where P < 0.05, a Bonferroni post hoc test was performed to determine the differences between each time point. The proportion meeting their requirements at each study visit was calculated by comparison with the relevant dietary reference value for energy (estimated average requirement) and protein (25) .
Results
The participant flow chart is provided in the supporting information ( Fig. S1 ): 80 patients were recruited; 68 completed the 3-month assessment and 57 completed the 12-month assessment. The baseline characteristics and treatment details of the 61 (76%) males and 19 (24%) females are shown in Table 1 . A number of patients had at least one consultation with a clinical dietitian as either an in-or outpatient in the 3-month period before baseline (32; 40%), in the baseline to 3-month period (45; 66.2%) and in the 3-month to 12-month period (42; 73.7%). The mean (SD) number of consultations with the clinical dietitian per patient, for the respective periods, was 1.6 (0.9), 3.2 (4.3) and 7.9 (7.4).
Nutritional status
The mean (SD) body weights at baseline (n = 80), 3 months (n = 68) and 12 months (n = 57) were: 76. were performed for those with data available at two (or more) time points, with significant reductions in weight and BMI as per the P-values: for baseline to 3 months, they were 0.003 and 0.006, respectively; for baseline to 12 months and also for 3 months to 12 months, they were <0.001 and <0.001, respectively. Of the patients with all data points, 12 (21%) gained weight from baseline to 12 months, with a mean percentage weight gain of 6.1%. The remaining 45 (79%) lost weight, with a mean percentage weight loss of 11.1% over the 12-month period.
The scores from the components of PG-SGA are provided in the supporting information (Table S1 ). The proportion experiencing recent unintentional weight loss decreased from 57.5% at baseline to 42.7% at 3 months and 26.3% at 12 months. For worksheet 4 (nutritionrelated physical examination and anthropometric assessment), at least 30% of patients were found to have some depletion of fat and muscle stores (and/or the presence of ascites/oedema). The prevalence of moderate/suspected/ severe malnutrition was 61.2% at baseline, 61.8% at 3 months and 59.6% at 12 months (Table 2) . No significant difference in PG-SGA score between any time points was identified.
Using cross-tabulation, it was noted that, from baseline to 12 months (n = 57), 14 (24.6%) patients improved their nutritional status category, 16 (28%) worsened their category and 27 (47.4%) remained stable. Nineteen (33%) patients were moderately/severely malnourished at both diagnosis and 12 months (i.e. malnutrition 'persisted'), whereas 15 (27%) were well-nourished at *PG-SGA total score is expressed as median (minimum -maximum). PG-SGA category scores are expressed as counts (%). PG-SGA, Patient-Generated Subjective Global Assessment.
diagnosis but became moderately/severely malnourished by 12 months (i.e. malnutrition 'developed').
Association between gastrointestinal symptoms and nutritional status
The median (range) GSRS total score was 12 of 66 (0-46) at baseline (n = 80), 9.5 of 66 (0-39) at 3 months (n = 68) and 12 of 66 (0-46) at 12 months (n = 57). There was moderate correlation between GSRS total score and PG-SGA total score at baseline (r = 0.55, P < 0.001), 3 months (r = 0.51, P < 0.001) and 12 months (r = 0.42, P = 0.001). At baseline, there was a greater prevalence of moderate/severe malnutrition in patients with 11 individual GI symptoms (dysphagia to solids, dysphagia to fluids, odynophagia to solids, odynophagia to fluids, belching, nausea, early satiety, abdominal grumbling, hard stools, constipation, incomplete evacuation) and, at 3 months, there was a greater prevalence for only three GI symptoms (early satiety, constipation and incomplete evacuation). There were no significant differences in prevalence of malnutrition between those with and without GI symptoms at 12 months (Table 3) . Pearson chi-squared tests were undertaken to determine the association between individuals with/without a symptom and PG-SGA category A or category B + C. Fisher's exact tests were performed where the expected cell count was less than 5. Data are presented for the association of the presence of a symptom and SGA B + C, where *P < 0.05; **P < 0.01; ***P < 0.001. Data were incomplete. Baseline: n = 79 for odynophagia to fluids, heartburn, faecal incontinence, hard stool; n = 78 for regurgitation of solids, loose stool; n = 76 for flatulence; n = 72 for constipation. Three months: n = 67 for odynophagia to fluids, heartburn, loose stool. Twelve months; n = 56 for heartburn.
Dietary intake
Seventy-eight FFQs were analysed at baseline, 61 at 3 months and 53 at 12 months. Of these patients, there were only 29 (37.2%) at baseline, 23 (37.7%) at 3 months and 22 (41.5%) at 12 months meeting their estimated average requirement for energy from food, although more were achieving their dietary reference value for protein at baseline (62; 79.5%), 3 months (54; 88.5%) and 12 months (48; 90.6%). Forty-three patients completed a FFQ at all three visits, and the mean energy and protein intake kg -1 day -1 was: 29.9 kcal kg À1 and 1.3 g kg À1 at baseline; 30.5 kcal kg À1 and 1.2 g kg À1 at 3 months; and 31.9 kcal kg À1 and 1.3 g kg À1 at 12 months. Results for the comparison of daily energy, fibre, nutrient and food group intakes at each visit are provided in the supporting information (Table S2 ). There was no significant change in the intake of any of the variables over time following Bonferroni post hoc testing, where relevant.
Discussion
This is the first study to record systematically nutritional status using a validated assessment method in OG cancer during the first year after diagnosis. Cancers of the GI tract are known to exert higher nutritional risk than other cancer sites (1, 3, 26) . The prevalence study of Hebuterne et al. (3) indicated that patients with OG cancer had the second highest prevalence of malnutrition (60%) after pancreatic cancer. This supports earlier work where 61% of newly diagnosed OG cancer patients were shown to have >5% unintentional weight loss (1) . In the present study, the prevalence of malnutrition was found to be 61% at baseline and this value remained unchanged over time.
Although the overall values for malnutrition prevalence remained stable, this reflects a dynamic process of improvement, deterioration and maintenance in different patients. Of those who were malnourished at baseline, this persisted until 12 months in one-third, whereas, of those who were well-nourished at baseline, one-quarter developed malnutrition by 12 months, meaning that malnutrition persisted or developed in the majority.
Although we were already aware that GI symptoms are observed in OG cancer patients (11) (12) (13) , until now, we were unclear about their co-occurrence with malnutrition. The results of the present study demonstrate a moderate correlation between symptom and nutritional status scores throughout this first year. Importantly, we now have specific GI symptoms (in particular dysphagia, odynophagia, nausea, abdominal pain and early satiety) that we know to be associated with poorer nutritional status ( Table 3) . We know that, by 12 months, most study patients no longer had cancer and so we suspect that their poor nutritional status had less to do with the primary effect of the cancer (i.e. imbalance between proand anti-inflammatory cytokines and abnormalities in substrate metabolism) and more to do with GI symptom burden.
The present study supports the argument that the multidisciplinary approach towards treatment decisions should be expanded to include much more active assessment and management of acute and chronic GI symptoms, with the aim of preventing them from negatively affecting nutritional status (27) . Likewise, an inadequate oral intake may contribute to malnutrition in OG cancer, although there are few studies assessing dietary intake in these patients. Considering these findings, and given that there was no increase in energy or protein intakes during the course of the present study, we suggest that the chronic energy and protein deficits contributed, at least in part, to the ongoing weight loss observed. These data are concerning, considering that, after the commencement of treatment, the majority had at least one consultation with a clinical dietitian and many were taking oral nutritional supplements. This questions the effectiveness of current interventions (predominately food fortification advice and oral nutritional supplementation) and suggests that earlier and more intensive input (i.e. enteral support) may be necessary to prevent nutritional decline.
Best practice guidelines advocate for early identification and commencement of nutrition intervention to maintain quality of life (1, 29, 30) . Also, the nutritional benefits of an early and intensive intervention (weekly dietetic consultations for 18 weeks) in OG cancer were demonstrated in a pilot study (31) , with a 6-kg greater weight and a 10-point lower PG-SGA score in the intervention group compared to standard care group. Larger, well-conducted RCTs are required to better understand the effectiveness of intensive interventions.
Strengths and limitations
The decision to include patients with Barrett's oesophagus or a premalignancy may represent a limitation of the present study considering that these patients do not usually have dysphagia or weight loss at presentation. However, this should not materially affect the results because these patients were so few (n = 4). Also of note, the groups of patients were not evenly distributed, as the majority were men. Many of the assessment methods relied to varying extents on recall and therefore may be prone to recall bias.
Another weakness relates to the FFQ, which significantly overestimates energy and fibre intake, as well as many macro-and micronutrients compared to weighed records (19) . This means that caution should be used in applying the estimates to individual diets. In addition, the dietary reference values provide a guide to the adequacy of dietary intake among healthy populations and therefore do not necessarily reflect the requirements of patients with cancer (32) . Therefore, any interpretation of the FFQ data must be conducted with caution.
The strength of the present study lies in its longitudinal design, which is atypical in cancer research concerned with nutrition because the majority of data come from crosssectional studies. By following the course of nutritional status, dietary intake and GI symptoms over one year, these results highlight the importance of a comprehensive assessment from diagnosis, acutely during treatment, as well as chronically. Attrition as a result of death is inevitable in the context of longitudinal research in cancer patients and this accounted for 18% of patients. However, the withdrawal and loss to follow-up rate were low at 11%. Neither inter-investigator bias, nor non-random sampling are relevant here because one researcher completed all of the assessments and the recruited and declined populations were comparable (data not presented).
In conclusion, those individuals with OG cancer experience a progressive weight loss over time and malnutrition is present in the majority during the first year. Current detection and treatment processes appear to be sub-optimal. Optimising nutritional status throughout the treatment pathway should be considered as a priority in this high-risk group. We suggest the need for an intensive approach, which might include weekly nutritional assessment during oncological treatments, and follow-up after their completion until no further risk exists. Ongoing assessment of GI function can be incorporated into the dietitian's assessments, as well as other relevant healthcare providers. Because the present study demonstrates that symptom burden shows an association with nutritional status, where the presence of symptoms tends to be associated with poorer nutritional status and vice versa, it is reasonable to hypothesise that the effective treatment of GI symptoms that are negatively impacting on dietary intake would improve nutritional status.
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